Ann: RAP Licenses Additional Pneumonia Diagnostic from UniQuest, page-93

Hi @jkshares

If you mean "wake up" with respect to movement in the SP, I would probably disagree. Until we have clarity around, firstly, completion of the US trials and, secondly, FDA approval, I can't see the SP moving too far from current. Perhaps we will have a run up (as @vwboy alluded to in his previous post) as we near the expected release dates for those announcements, otherwise I think we are reasonably range bound, and in fact fully priced pending the outcome of those key announcements.

Just my thoughts on an idle Monday morning here in NZ.

Roy